Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03342573 · ClinicalTrials.gov registry record · Phase 1
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03342573: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03342573 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03342573, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.
Interventions
- DRUG Cosentyx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2022-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03342573
The ClinicalTrials.gov registry entry for NCT03342573 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cosentyx is the first listed.
NCT03342573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03342573 about?
NCT03342573 is a clinical study titled "Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris". The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.
What is the current status of trial NCT03342573?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-04-01. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT03342573?
The interventions under investigation include: Cosentyx (DRUG).
Who is sponsoring clinical trial NCT03342573?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.